http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021110886-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c47ab152647cefce45d8ea0a09b91d0e
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B5-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
filingDate 2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56c0d9c2520d420d4eef6a712e61d7e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8131afdeb91c87fdd702a009815327b1
publicationDate 2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021110886-A1
titleOfInvention Gene expression signature of hyperprogressive disease (hpd) in patients after anti-pd-1 immunotherapy
abstract A method of determining a patient's HPD status comprising the steps of a) examining a patient tumor sample for the expression level of HPD-diagnostic biomarkers, and b) determining whether the signature of the biomarkers is similar to that of a HPD positive signature is disclosed.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023125910-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113764100-A
priorityDate 2019-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420343
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6331297
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5287620
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395931
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226433117
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226433116
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5352006
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID857
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123596
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4101
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57472993
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416392
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416391
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID320930

Total number of triples: 54.